The Effect of Spironolactone on Acute Kidney Injury After Cardiac Surgery: A Randomized, Placebo-Controlled Trial

American Journal of Kidney Diseases

Volumn 69, Issue 2, 2017, Pages 192-199

  Barba Navarro, Rubén ^a   Tapia Silva, Mirell ^a   Garza Garcia, Carlos ^a   López Giacoman, Salvador ^a   Melgoza Toral, Ipsae ^a   Vázquez Rangel, Armando ^a   Bazúa Valenti, Silvana ^b,d   Bobadilla, Norma ^b,d   Wasung de Lay, Michael ^a   Baranda, Francisco ^a   Chawla, Lakhmir S ^c   Gamba, Gerardo ^b,d   Madero, Magdalena ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acute kidney injury (AKI); cardiac surgery; cardiopulmonary bypass; mineralocorticoid receptor blocker; randomized controlled trial (RCT); renal ischemia; spironolactone

Indexed keywords

CREATININE; PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HEART SURGERY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SURGICAL PATIENT; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; INTENSIVE CARE UNIT; POSTOPERATIVE COMPLICATIONS;

ACUTE KIDNEY INJURY; CARDIAC SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POSTOPERATIVE COMPLICATIONS; SPIRONOLACTONE;

EID: 84994430570     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.06.013     Document Type: Article

References (42)

1. 1 Mehta, R., Grab, J., O'Brien, S., et al. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation 114 (2006), 2208–2216.
2. 2 Rosner, M.H., Okusa, M.D., Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 1:1 (2006), 19–32.
3. 3 Thakar, C.V., Worley, S., Arrigain, S., Yared, J.P., Paganini, E.P., Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int 67:3 (2005), 1112–1119.
4. 4 Mangano, C.M., Diamondstone, L.S., Ramsay, J.G., Aggarwal, A., Herskowitz, A., Mangano, D.T., The Multicenter Study of Perioperative Ischemia Research Group. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 128:3 (1998), 194–203.
5. 5 Ryckwaert, F., Boccara, G., Frappier, J.M., Colson, P.H., Incidence, risk factors, and prognosis of a moderate increase in plasma creatinine early after cardiac surgery. Crit Care Med 30:7 (2002), 1495–1498.
6. 6 Abel, R.M., Buckley, M.J., Austen, W.G., Barnett, G.O., Beck, C.H. Jr., Fischer, J.E., Etiology, incidence, and prognosis of renal failure following cardiac operations: results of a prospective analysis of 500 consecutive patients. J Thorac Cardiovasc Surg 71:3 (1976), 323–333.
7. 7 Bhat, J.G., Gluck, M.C., Lowenstein, J., Baldwin, D.S., Renal failure after open heart surgery. Ann Intern Med 84:6 (1976), 677–682.
8. 8 Coppolino, G., Presta, P., Saturno, L., Fuiano, G., Acute kidney injury in patients undergoing cardiac surgery. J Nephrol 26:01 (2013), 32–40.
9. 9 Coca, S.G., Yusuf, B., Shilpak, M.G., Garg, A.X., Parikh, C.R., Long term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 53 (2009), 961–973.
10. 10 Chawla, L.S., Amdur, R.L., Amodeo, S., Kimmel, P.L., Palant, C.E., The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 79 (2011), 1361–1369.
11. 11 Tang, A.T., El-Gamel, A., Keevil, B., Yonan, N., Deiraniya, A.K., The effect of ‘renal-dose’ dopamine on renal tubular function following cardiac surgery: assessed by measuring retinol binding protein (RBP). Eur J Cardiothorac Surg 15 (1999), 717–721.
12. 12 Lassnigg, A., Donner, E., Grubhofer, G., Presterl, E., Druml, W., Hiesmayr, M., Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 11 (2000), 97–104.
13. 13 Lombardi, R., Ferreiro, A., Servetto, C., Renal function after cardiac surgery: adverse effect of furosemide. Ren Fail 25 (2003), 775–786.
14. 14 Ranucci, M., Soro, G., Barzaghi, N., et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 78 (2004), 1332–1337.
15. 15 Kramer, B.K., Preuner, J., Ebenburger, A., et al. Lack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant 17 (2002), 910–915.
16. 16 Carcoana, O.V., Mathew, J.P., Davis, E., et al. Mannitol and dopamine in patients undergoing cardiopulmonary bypass: a randomized clinical trial. Anesth Analg 97 (2003), 1222–1229.
17. 17 Sward, K., Valsson, F., Odencrants, P., Samuelsson, O., Ricksten, S.E., Recombinant human atrial natriuretic peptide in ischemic acute renal failure. A randomized placebo controlled trial. Crit Care Med 32 (2004), 1310–1315.
18. 18 Boldt, J., Brosch, C., Piper, S.N., Suttner, S., Lehmann, A., Werling, C., Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med 29 (2001), 952–958.
19. 19 Prowle, J.R., Calzavacca, P., Licari, E., et al. Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery. Nephrology (Carlton) 17:3 (2012), 215–224.
20. 20 Bonventre, J.V., Weinberg, J.M., Recent advances in the pathophysiology of isquemic acute renal failure. J Am Soc Nephrol 14 (2003), 2199–2210.
21. 21 Arima, S., Kohagura, K., Xu, H.L., et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14:9 (2003), 2255–2263.
22. 22 Leopold, J.A., Dam, A., Maron, B.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13:2 (2007), 189–197.
23. 23 Mejia-Vilet, J.M., Ramirez, V., Cruz, C., Uribe, N., Gamba, G., Bobadilla, N.A., Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293 (2007), F78–F86.
24. 24 Sanchez-Pozos, K., Barrera-Chimal, J., Garzón-Muvdi, J., et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant 27 (2012), 3160–3169.
25. 25 Moguel-González, B., Wasung-de-Lay, M., Tella-Vega, P., et al. Acute kidney injury in cardiac surgery. Rev Invest Clin 65:6 (2013), 467–475.
26. 26 Thakar, C.V., Arrigain, S., Worley, S., Yared, J.P., Paganini, E.P., A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 16:1 (2005), 162–168.
27. 27 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2 (2012), 1–138.
28. 28 Ramirez, V., Trujillo, J., Valdes, R., et al. Adrenalectomy prevents renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 297 (2009), F932–F942.
29. 29 Barrera Chimal, J., Pérez-Villalva, R., Rodríguez-Romo, R., et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 83:1 (2013), 93–103.
30. 30 Barrera-Chimal, J., Prince, S., Fadel, F., et al. Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. J Am Soc Nephrol 27:2 (2016), 398–404.
31. 31 Dorrance, A.M., Osborn, H.L., Grekin, R., Webb, R.C., Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 281:3 (2001), R944–R950.
32. 32 Chai, W., Garrelds, I.M., Arulmani, U., Schoemaker, R.G., Lamers, J.M., Danser, A.H., Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?. Br J Pharmacol 145:5 (2005), 664–671.
33. 33 Pretorius, M., Murray, K.T., Yu, C., et al. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med 40:10 (2012), 2805–2812.
34. 34 Cremer, J., Martin, M., Redl, H., et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 61:6 (1996), 1714–1720.
35. 35 Sheridan, A.M., Bonventre, J.V., Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens 9:4 (2000), 427–434.
36. 36 Sreeram, G.M., Grocott, H.P., White, W.D., Newman, M.F., Stafford-Smith, M., Transcranial Doppler emboli count predicts rise in creatinine after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 18:5 (2004), 548–551.
37. 37 Blauth, C.I., Macroemboli and microemboli during cardiopulmonary bypass. Ann Thorac Surg 59:5 (1995), 1300–1303.
38. 38 Parekh, D.J., Weinberg, J.M., Ercole, B., et al. Tolerance of the human kidney to isolated controlled ischemia. J Am Soc Nephrol 24:3 (2013), 506–517.
39. 39 Yamamoto, T., Noiri, E., Ono, Y., et al. Renal L-type fatty acid–binding protein in acute ischemic injury. J Am Soc Nephrol 18:11 (2007), 2894–2902.
40. 40 The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78 (1996), 902–907.
41. 41 Lee, N.V., Miller, P.W., Buono, M.J., The effect of spironolactone on sweat and urinary sodium excretion during exercise in humans. Clin Physiol Funct Imaging 30:1 (2010), 13–16.
42. 42 Skali, H.1, Uno, H., Levey, A.S., Inker, L.A., Pfeffer, M.A., Solomon, S.D., Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 162:3 (2011), 548–554.